Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) saw a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 15,900 shares, a growth of 37.1% from the November 15th total of 11,600 shares. Based on an average daily trading volume, of 33,200 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.4% of the shares of the company are sold short.

Insider Buying and Selling

In other news, major shareholder Alexander Schornstein acquired 10,000 shares of Assembly Biosciences stock in a transaction on Tuesday, October 8th. The stock was acquired at an average cost of $14.58 per share, with a total value of $145,800.00. Following the completion of the acquisition, the insider now owns 703,113 shares in the company, valued at approximately $10,251,387.54. This trade represents a 1.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 394 shares of company stock valued at $5,894. 5.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC boosted its position in shares of Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 7,690 shares during the period. FMR LLC increased its holdings in Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 3,635 shares during the period. Renaissance Technologies LLC lifted its stake in Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 15,451 shares in the last quarter. Finally, Armistice Capital LLC bought a new position in Assembly Biosciences in the 2nd quarter valued at $6,421,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ASMB. Jefferies Financial Group raised Assembly Biosciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $2.00 to $35.00 in a report on Friday, September 20th. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research note on Tuesday, September 24th.

Assembly Biosciences Price Performance

Shares of NASDAQ ASMB traded up $0.03 during mid-day trading on Friday, hitting $15.38. The company had a trading volume of 10,278 shares, compared to its average volume of 24,476. Assembly Biosciences has a 1 year low of $8.82 and a 1 year high of $19.93. The stock’s 50-day moving average price is $16.42 and its 200-day moving average price is $15.59.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.